FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281642685> ?p ?o ?g. }

• W4281642685 endingPage "11535" @default.
• W4281642685 startingPage "11535" @default.
• W4281642685 abstract "11535 Background: Life-long tyrosine kinase inhibitor (TKI) treatment is recommended for patients (pts) with metastatic GIST. We investigated whether highly selected pts with metastatic GIST may remain in durable complete remission after imatinib discontinuation. Methods: In this 1-group, prospective, multicenter phase II trial (NTC02924714) selected pts with overtly metastatic GIST discontinued imatinib treatment. Eligible pts had been treated with imatinib > 5 yrs for oligo-metastatic (≤3 metastases) disease, had no GIST progression and had undergone either R0/R1 resection or radiofrequency ablation (RFA) of all metastases, and had no longer detectable metastases on CT/MRI imaging, The primary endpoint was 3-yr progression-free survival (PFS), overall survival was a secondary endpoint. We estimated to achieve an improvement from 15% to 35% in 3-yr PFS compared to pts treated in the BRF-14 trial with a sample size of 31 pts. Results: The trial closed early due to slow accrual. Between January 5, 2017, and June 5, 2019, 12 pts (males, 7) with a median age of 67 yrs (range, 50-85) were enrolled. All pts had their primary tumor surgically removed (stomach, 4; small bowel, 6; large bowel/rectum, 2). Seven pts had KIT exon 11 mutation, 2 KIT exon 9 mutation, 1 PDGFRA exon 12 mutation, 1 had no mutation in KIT/PDGFRA, and 1 pt had unknown GIST mutational status. Eight pts had liver metastases, 3 peritoneal metastases, and 1 had both. Prior to enrollment all pts were in macroscopic complete remission after surgical metastasectomy (n = 7), RFA (n = 2), or both (n = 1), and 1 pt achieved complete radiological response with imatinib. At enrollment, 8 pts had imatinib 400 mg/d and 4 had < 400 mg/d. The median time of imatinib treatment before study entry was 8 yrs (range, 5-17). After imatinib discontinuation 7 (58%) pts progressed; the median time to progression was 10 mos (range, 2-31 mos). Five (42%) patients were progression-free after a median follow-up time of 42 mos (range, 30-59 mos). Median PFS was 23 mos and the estimated 3-year PFS 39%. Patients who progressed all achieved a second remission after restarting imatinib and were alive after a median follow-up time of 48 mos (range, 32 to 61 mos). Conclusions: The findings suggest that discontinuation of imatinib is safe in highly selected patients with oligo-metastatic GIST and that such patients may survive without detectable GIST progression for several years. The findings need to be viewed with caution due to the small pt numbers. Further study on imatinib discontinuation seem warranted. Clinical trial information: NCT02924714." @default.
• W4281642685 created "2022-06-13" @default.
• W4281642685 creator A5009097210 @default.
• W4281642685 creator A5011277446 @default.
• W4281642685 creator A5023432706 @default.
• W4281642685 creator A5035939033 @default.
• W4281642685 creator A5056376346 @default.
• W4281642685 creator A5090618504 @default.
• W4281642685 date "2022-06-01" @default.
• W4281642685 modified "2023-10-17" @default.
• W4281642685 title "Discontinuation of imatinib in patients with oligo-metastatic gastrointestinal stromal tumor who are in complete radiological remission: A prospective multicenter phase II study." @default.
• W4281642685 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.11535" @default.
• W4281642685 hasPublicationYear "2022" @default.
• W4281642685 type Work @default.
• W4281642685 citedByCount "1" @default.
• W4281642685 countsByYear W42816426852023 @default.
• W4281642685 crossrefType "journal-article" @default.
• W4281642685 hasAuthorship W4281642685A5009097210 @default.
• W4281642685 hasAuthorship W4281642685A5011277446 @default.
• W4281642685 hasAuthorship W4281642685A5023432706 @default.
• W4281642685 hasAuthorship W4281642685A5035939033 @default.
• W4281642685 hasAuthorship W4281642685A5056376346 @default.
• W4281642685 hasAuthorship W4281642685A5090618504 @default.
• W4281642685 hasConcept C121608353 @default.
• W4281642685 hasConcept C126322002 @default.
• W4281642685 hasConcept C141071460 @default.
• W4281642685 hasConcept C143998085 @default.
• W4281642685 hasConcept C16930146 @default.
• W4281642685 hasConcept C203092338 @default.
• W4281642685 hasConcept C2775922572 @default.
• W4281642685 hasConcept C2777007597 @default.
• W4281642685 hasConcept C2777583451 @default.
• W4281642685 hasConcept C2778601017 @default.
• W4281642685 hasConcept C2778715236 @default.
• W4281642685 hasConcept C2778729363 @default.
• W4281642685 hasConcept C2779013556 @default.
• W4281642685 hasConcept C37307934 @default.
• W4281642685 hasConcept C535046627 @default.
• W4281642685 hasConcept C71924100 @default.
• W4281642685 hasConcept C90924648 @default.
• W4281642685 hasConceptScore W4281642685C121608353 @default.
• W4281642685 hasConceptScore W4281642685C126322002 @default.
• W4281642685 hasConceptScore W4281642685C141071460 @default.
• W4281642685 hasConceptScore W4281642685C143998085 @default.
• W4281642685 hasConceptScore W4281642685C16930146 @default.
• W4281642685 hasConceptScore W4281642685C203092338 @default.
• W4281642685 hasConceptScore W4281642685C2775922572 @default.
• W4281642685 hasConceptScore W4281642685C2777007597 @default.
• W4281642685 hasConceptScore W4281642685C2777583451 @default.
• W4281642685 hasConceptScore W4281642685C2778601017 @default.
• W4281642685 hasConceptScore W4281642685C2778715236 @default.
• W4281642685 hasConceptScore W4281642685C2778729363 @default.
• W4281642685 hasConceptScore W4281642685C2779013556 @default.
• W4281642685 hasConceptScore W4281642685C37307934 @default.
• W4281642685 hasConceptScore W4281642685C535046627 @default.
• W4281642685 hasConceptScore W4281642685C71924100 @default.
• W4281642685 hasConceptScore W4281642685C90924648 @default.
• W4281642685 hasIssue "16_suppl" @default.
• W4281642685 hasLocation W42816426851 @default.
• W4281642685 hasOpenAccess W4281642685 @default.
• W4281642685 hasPrimaryLocation W42816426851 @default.
• W4281642685 hasRelatedWork W1964805506 @default.
• W4281642685 hasRelatedWork W2004598454 @default.
• W4281642685 hasRelatedWork W2020689705 @default.
• W4281642685 hasRelatedWork W2067256453 @default.
• W4281642685 hasRelatedWork W2128064909 @default.
• W4281642685 hasRelatedWork W2412807435 @default.
• W4281642685 hasRelatedWork W2991103064 @default.
• W4281642685 hasRelatedWork W3044902401 @default.
• W4281642685 hasRelatedWork W3157027491 @default.
• W4281642685 hasRelatedWork W4281642685 @default.
• W4281642685 hasVolume "40" @default.
• W4281642685 isParatext "false" @default.
• W4281642685 isRetracted "false" @default.
• W4281642685 workType "article" @default.